By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Newron Pharmaceuticals 

Via R. Lepetit
Gerenzano      Italy
Phone: 39-02-9668131 Fax: 39-02-96681333



Company News
Newron Pharma (NWRN) Release: FDA Approves Xadago (Safinamide) For Parkinson's Disease (PD) Patients 3/22/2017 6:51:57 AM
Newron Pharma (NWRN) To Present At The 16th International Congress On Schizophrenia Research 3/16/2017 6:47:23 AM
Newron Pharma (NWRN) Announces 2016 Financial Results And Provides Outlook For 2017 3/2/2017 6:24:18 AM
Newron Pharma (NWRN) Supports Global Rare Disease Day 2017 And Rett Syndrome Studies 2/21/2017 10:54:24 AM
Newron Pharma (NWRN) Announces Encouraging Preliminary Results Of Its Phase IIa Study With Evenamide In Patients With Schizophrenia 1/3/2017 11:16:25 AM
Change In Newron Pharma (NWRN)’s Senior Management Team 12/27/2016 11:29:35 AM
Newron Pharma (NWRN) Supports Rett Syndrome Awareness Month 10/24/2016 8:42:53 AM
U.S. FDA Considers Newron Pharma (NWRN)'s Re-Submitted NDA For Xadago To Be A Complete, Class 2 Response To Complete Response Letter 10/21/2016 11:11:55 AM
Newron Pharma (NWRN) Re-submits U.S. NDA For Xadago (Safinamide) 9/22/2016 10:44:52 AM
Newron Pharma (NWRN) Reports Half-Year 2016 Results 9/15/2016 11:35:22 AM